Navigating New and Emerging Therapeutic Targets to Optimize Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and the Role of the Pharmacist

Program Description

Generalized myasthenia gravis (gMG) can result in significant disease burden for patients due to fluctuating, often severe, muscle weakness, debilitating fatigue, and if left without optimal treatment, a high potential for exacerbation or respiratory crises. Research into the pathophysiology of gMG has uncovered several immunopathologic mechanisms contributing to the disease, particularly the critical roles of autoantibodies, complement activation, and the neonatal Fc receptor (FcRn). This session will provide specialty pharmacists with a foundational understanding of gMG pathophysiology and the latest approved agents, including FcRn inhibitors, complement inhibitors, and B-cell–directed therapies, with a review of their mechanism of action, efficacy, and safety profiles. It will also review recent data involving these agents that could affect practice in the years to come. Timely and appropriate care for patients with gMG is critical. By reviewing these new and emerging treatments and detailing the responsibilities of the pharmacist in care coordination, patient education, adherence monitoring, and adverse effect management, this session will support specialty pharmacists in successfully navigating the treatment landscape of gMG. Patient case discussion will also be incorporated, providing opportunities to apply knowledge of gMG management and treatment selection to complex, real-world patient scenarios.

Target audience: Specialty pharmacists
Type of activity: Application
Release date: July 29, 2026
Expiration date: July 29, 2027
Learner level: Foundational
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Describe the underlying disease mechanisms of gMG and how advances in pathophysiologic understanding have informed the development of targeted therapeutic approaches. 
• Review the mechanisms of action, clinical efficacy, and safety considerations associated with FDA-approved and emerging targeted therapies for gMG. 
• Apply evidence-based, multidisciplinary care principles to support the appropriate integration of targeted therapies while individualizing treatment strategies to enhance patient quality of life.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-251-H01-P. The activity is available for CE credit through July 29, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Erica Marini, PharmD, MS, BCPS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Sarah Viruet; and Brianna Winters.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms